her2-positive
Entity, reached from Hormuz.
- Evidence
- 39 documents · 14 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 5 May 2026, last seen 7 Oct 2026
- Measured
- 23% of mentions say something specific about it; the rest only name it
- As of
- 10 Oct 2026
Where this comes from
- medRxiv Oncology · 2026-10-07 · Multimodal Artificial Intelligence Predicts Pathological Response and Prognosis in HER2-Positive Early Breast Cancer Treated with Chemotherapy De-escalation Strategies… (opens the source in a new tab)
- FDA · 2026-10-07 · FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-09-25 · Individualized treatment of HER2-positive breast cancer patients with lung metastasis using a circulating tumor cell drug sensitivity test: a case report (opens the source in a new tab)
- Nature Medicine · 2026-09-22 · Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial (opens the source in a new tab)
- The ASCO Post · 2026-09-04 · Predictors of pCR to Neoadjuvant THP Explored in HER2-Positive Breast Cancer (opens the source in a new tab)
- FDA Drug News · 2026-06-25 · [APPROVAL] FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metast… (opens the source in a new tab)
- FDA Drug News · 2026-05-16 · [APPROVAL] FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer (opens the source in a new tab)
Links from here: not yet read.
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with her2 (39 documents)seen together
- co-mentioned with breast cancer (23 documents)seen together
- co-mentioned with colorectal cancer (19 documents)seen together
- co-mentioned with immunotherapy (14 documents)seen together
- co-mentioned with studie (14 documents)seen together
- co-mentioned with fda (12 documents)seen together
- co-mentioned with asco (11 documents)seen together
- co-mentioned with ai (11 documents)seen together
- co-mentioned with her2-directed (10 documents)seen together
- co-mentioned with her2-negative (9 documents)seen together